Chief Accounting Officer, VP of Fin. and ControllerMr. Gregory F. Covino is Chief Accounting Officer Vice President Finance of Biogen Idec Inc. since April 2012. Prior to that Mr. Covino served at Boston Scientific Corporationrationration a medical device company as Vice President Corporationrationrate Analysis and Control since March 2010 having responsibility for the company internal audit function and as Vice President Finance International from February 2008 to March 2010 having responsibility for the financial activities of the company international division. Prior to that Mr. Covino held several finance positions at Hubbell Incorporated an electrical products company including Vice President Chief Accounting Officer and Controller from 2002 to January 2008 Interim Chief Financial Officer from 2004 to 2005 and Director Corporationrationrate Accounting from 1999 to 2002
Age: 48 VP Since 2012
|Covino received his B.S. in Business Administration from Bryant University.|
The company has return on total asset (ROA) of 18.54 % which means that it generated profit of $18.54 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 35.6 % meaning that it created $35.6 on every $100 dollars invested by stockholders.
Filter Other Executives
Entity SummaryBiogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. Biogen Inc [BIIB] is traded on NASDAQ in USA. It is located in Cambridge, MA and employs 7,350 people.
|Biogen Inc. discovers develops manufactures and delivers therapies for the treatment of neurodegenerative diseases hematologic conditions and autoimmune disorders. more|
|Analyst Consensus||Buy 21 Opinions|
|Macroaxis Advice||Cautious Hold Under Valued|
|Average Bond Rating||BBB Adequate|
|Currency||USD - US Dollar|
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Biogen Inc to your portfolio